EP Patent

EP0425154A1 — Sustained release elements

Assigned to Dow Silicones Belgium SPRL · Expires 1991-05-02 · 35y expired

What this patent protects

The invention is concerned with a sustained release element and its manufacture. The element comprises an agent (A) capable of release from the element when the latter is in an aqueous environment and a vehicle (B) therefor, the vehicle (B) comprising a hydrophilic componen…

USPTO Abstract

The invention is concerned with a sustained release element and its manufacture. The element comprises an agent (A) capable of release from the element when the latter is in an aqueous environment and a vehicle (B) therefor, the vehicle (B) comprising a hydrophilic component such as propylene glycol, liquid polyethylene glycols or glycerol, a silicone polymer and a modulating component, such as a polyhydroxylated organic substance or a hydrophilic polymer which swells in an aqueous medium, such as a cellusolve derivative. This element is useful particularly for affording controlled release of therapeutic or diagnostic agents. In addition to controlled release, swelling properties, adhesion and/or floatability enable increased residence times to be achieved in the stomach, colon or on the mucosa of patients undergoing treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP0425154A1
Jurisdiction
EP
Classification
Expires
1991-05-02
Drug substance claim
No
Drug product claim
No
Assignee
Dow Silicones Belgium SPRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.